Novo Nordisk and Gilead Team up on NASH Trial

Apr 14, 2019 | Gilead, Leading Pharma, NASH, Novo Nordisk, Pharma Watch

Danish giant Novo Nordisk, a diabetes market leader, has partnered with San Francisco Bay Area-based Gilead to collaborate on a NASH clinical trial. The two industry sponsors will combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of patients with NASH.

Recently, a Gilead late-stage study of experimental drug selonsertib failed at meeting main goal during a NASH trial.  TrialSite News has written about the emerging NASH crisis. Some predict the NASH market to hit $35 billion as populations increasingly develop the disease.


Pin It on Pinterest